The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Is there a clinical benefit in testing for UGT1A1*28 prior to irinotecan therapy?
Bihani Yoshana Kularatne
No relevant relationships to disclose
Anthony Marinaki
No relevant relationships to disclose
Vasilis Karavasilis
No relevant relationships to disclose
James F. Spicer
No relevant relationships to disclose
Paul J. Ross
No relevant relationships to disclose
Dimitrios G. Pectasides
No relevant relationships to disclose
Thomas Makatsoris
No relevant relationships to disclose
George E. Pentheroudakis
No relevant relationships to disclose
George Fountzilas
No relevant relationships to disclose